There is a growing trend for pharmaceutical companies to seek scientiﬁc advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efﬁciency of their studies, enable better trial design, and support the goals of positive HTA recommendation for reimbursement. This study uses information collected directly from companies on individual products to assess their strategies and practices for seeking HTA-related scientiﬁc advice in terms of which stakeholders to engage and for what purpose, when to seek scientiﬁc advice, and whether to implement that advice within global clinical development.
Wang T, McAuslane N, Gardarsdottir H, Goettsch WG, Leufkens HGM. Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies [published online ahead of print, 2021 Sep 28]. Drug Discov Today. 2021;S1359-6446(21)00408-6. doi:10.1016/j.drudis.2021.09.014